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Abstract: Decades of basic science and clinical research have led to an increased 
understanding of the pathophysiology of immune thrombocytopenic purpura (ITP), the processes 
underlying thrombopoiesis, and the treatment of chronic ITP. Now, new agents are available 
to treat ITP in a nonimmunosuppressive fashion. Lessons learned from the clinical trials of 
recombinant human thrombopoietin (TPO) have led to the development of a novel class of 
compounds: nonimmunogenic agonists of the thrombopoietin receptor. Representing the first 
nonimmunosuppressive agents to treat chronic refractory ITP in decades, medications such as 
romiplostim and eltrombopag were recently approved by the US Food and Drug Administration. 
These new agents offer physicians a new tool for treating difficult cases of ITP in their medical 
armamentarium. Additional TPO mimetics are also being developed that show promise in vitro, 
and await future development.
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Introduction
When platelets fall below 150,000/µl, a patient is considered to have thrombocytopenia. 
Hemostasis can become compromised when the platelet count falls to less than 
50,000/µl and the risk for spontaneous hemorrhage is significantly increased at levels 
less than 20,000/µl. While the causes and diagnostic algorithms for thrombocytopenia 
are beyond the scope of this review, it can be delineated to three broad categories: 
1) increased destruction, as seen in immune thrombocytopenic purpura (ITP) or dis-
seminated intravascular coagulation, 2) decreased production, due to aplastic anemia 
or some other bone marrow production disorder, or 3) sequestration, as occurs in 
conditions leading to splenomegaly.
Because the differential diagnosis and treatment for thrombocytopenia is so exten-
sive and varied, a thorough history and physical examination, with attention to possible 
alternative explanations for thrombocytopenia is mandatory. Preliminary laboratory 
tests include a complete blood count with a differential, along with an examination of 
the peripheral blood smear. Any additional testing is based solely upon the available 
clinical information, eg, human immunodeficiency virus (HIV) testing in a patient 
with risk factors. Bone marrow biopsy should be reserved for older patients or in the 
evaluation of patients in whom standard therapy has not been effective. Determining the 
etiology of thrombocytopenia is essential in order to provide the proper treatment and 
to avoid unnecessary procedures and treatments.1,2 since the diagnosis of ITP remains 
one of exclusion.3 In order to understand the rationale of ITP treatment, a review of its Biologics: Targets & Therapy 2009:3 500
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history and advances in understanding the pathophysiology 
of this condition is necessary.
History of ITP treatment
Splenectomy was considered to be the first published treat-
ment for ITP, which was reported in 1916 by Kaznelson 
in Prague, as reviewed by Whipple.4 In Whipple’s review, 
Kaznelson reported 81 cases of thrombocytopenia, and he 
noted that splenectomy is “considered the greatest advance 
to the therapy of the purpuras” but he forewarned, “it should 
be emphasized that the patients after splenectomy should be 
cautioned and guarded against infections in order to obtain 
the best results.”
Splenectomy remained the sole treatment for ITP for over 
a quarter of a century until the introduction of corticosteroids 
in clinical practice. Adrenocorticotropic hormone (ACTH) 
was discovered to be effective for ITP,5 and later cortisone,6 
supplanting splenectomy as the primary treatment for ITP. 
Given that clinical remissions were possible with cortico-
steroids, their use remained the initial treatment choice for 
ITP for more than 50 years. The use of immunomodulatory 
agents in ITP was augmented by intravenous immunoglobulin 
(IVIg) or anti-D, and by alternative immunosuppressives for 
refractory ITP, such as cyclophosphamide,7 azathioprine,8 
interferon (IFN),9 cyclosporine A,10 mycophenolate mofetil,11 
dapsone,12 and etanercept.13 While danazol has also been 
used to treat refractory ITP,14 it is an attenuated androgen, 
and therefore, not an immunosuppressive in the conventional 
sense. The use of these alternative immunosuppressants 
and immunomodulators in chronic refractory ITP has been 
expertly summarized elsewhere.15
Since immunomodulation was the only effective treat-
ment of ITP, use of immunosuppressive agents, splenectomy, 
or immune modulators such as IVIg or anti-D was all that 
was available. Despite the many immunomodulatory agents 
that were available, a pressing need for alternative treat-
ments arose. This stemmed from the significant percentage 
of patients who relapsed after steroid taper, failed to respond 
to splenectomy, and who developed chronic and refractory 
thrombocytopenia.3 This challenging cohort of patients often 
have mortality related to the immunosuppression caused by 
the medications used to treat the thrombocytopenia than 
from bleeding.16 This leaves affected patients feeling that 
the treatment is often worse than the disease.17 For example, 
cyclophosphamide, azathioprine, and mycophenolate are 
immunosuppressive agents associated with an increased 
risk of infection in splenectomized patients. Danazol can 
lead to unfavorable lipid profiles, and can have virilizing 
effects on female patients. The limited efficacy of third line 
agents, along with the undesirable and potentially lethal 
side effects of commonly used immunosuppressives, helped 
spur research into discovering the complicated mechanisms 
of ITP.
Platelet underproduction in ITP
When bone marrow studies are performed on ITP patients, 
megakaryocyte hyperplasia is often noted, despite the 
decreased peripheral count. This observation led to the 
interpretation that despite the increase in the production of 
platelets, the peripheral destruction of platelets is able to 
out-pace their production, ultimately leading to thrombocy-
topenia. With refined research techniques over the ensuing 
decades, a number of observations called into question the 
validity of these suppositions, which ultimately has set the 
stage for the rationale and development of thrombopoietin 
(TPO) mimetics.
An early report noted that the megakaryocytes within the 
bone marrow of ITP patients were increased in number.18 
However, when compared to the bone marrow of patients 
with secondary forms of thrombocytopenia, eg, cirrhosis 
with splenomegaly, the megakaryocytes of both acute and 
chronic ITP patients were observed to have a reduction in 
platelet production. This observation of platelet hypo-pro-
duction had gone largely unnoticed, until platelet kinetic 
studies suggested and then helped elucidate the degree of 
bone marrow response in ITP.
In 1985, Stoll and colleagues examined the average 
life-span of platelets in patients with a moderate degree of 
thrombocytopenia with ITP.19 Autologous platelets labeled 
with 51Chromium (51Cr) were used instead of heterologous 
51Cr-labeled platelets. When compared to normal volunteers, 
the average life of the labeled platelet was reduced. However, 
the investigators noted that the rate of platelet production was 
practically equivalent to that of the normal volunteers, con-
cluding that the rate of platelet production was not increased 
in ITP.19 With the use of 111Indium-labeled platelets, it was 
observed that the platelet life-span was not as short as previ-
ously thought,20 and that the majority of patients with ITP 
did not have an increase in platelet production.21 This has 
led investigators to conclude that despite the hyperplasia of 
megakaryocytes in the bone marrow, “the predominant cause 
of thrombocytopenia is ineffective marrow platelet produc-
tion rather than accelerated platelet removal”.22 It should 
be noted that many patients enrolled in this trial had very 
mild ITP, and the few patients with severe ITP, who were 
studied by this method did have markedly shortened platelet Biologics: Targets & Therapy 2009:3 501
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survival. Therefore, one can conclude that platelet survival 
is variable in ITP; however, most patients with significant 
thrombocytopenia do have enhanced peripheral destruction 
of their platelets.
Discovery of thrombopoietin  
and its receptor
After the discovery of erythropoietin (Epo), it was extrapo-
lated that another humoral agent should exist which increases 
the platelet count. The term “thrombopoietin” was first used 
in 1958, when it was observed that sera injected into mice 
from patients with thrombocytosis caused an increase in the 
platelet count. This unknown substance was characterized as 
a protein, and the authors concluded that this serum “throm-
bopoietin” existed in equilibrium with an inhibitor.23 Further 
evidence for this equilibrium was observed when researchers 
transfused “viable platelets” into thrombocytopenic rats, 
with subsequent diminution of thrombopoiesis. Based upon 
these experiments and observations, the authors accurately 
postulated nearly half a century ago that “platelet production 
is regulated by the circulating platelets themselves”.24
Meanwhile, the search for the proposed “thrombopoietin” 
continued for more than 40 years, and numerous cytokines 
were proposed as possible candidates, among which included 
interleukin (IL)-1α, IL-6, and IL-11. While these cytokines 
were capable of increasing the platelet count, it was not until 
the identification of murine leukemia virus that the discovery 
of TPO was accomplished.
Discovery of the thrombopoietin 
receptor, Mpl
In 1986, researchers in France found a variant of the Friend 
helper ecotropic virus, one that caused thrombocytosis 
instead of pancytopenia in mice. It was named myleprolif-
erative leukemia virus (MPLV), the genome of this virus 
contained a novel oncogene, v-mpl, that was found to have a 
well conserved mammalian homolog, c-mpl, which mapped 
to chromosome 1p34.25,26 When transfected into mammalian 
bone marrow cells, expression of v-mpl caused their immor-
talization, and when c-mpl was eventually cloned, it was 
found to have sequence homology with the hematopoietic 
receptor superfamily.27,28 Antagonism of c-mpl via anti-sense 
DNA technology led to a reduction in megakaryocyte colony 
forming units, but not in the erythroid or granulocytic lin-
eages. This showed that proper function of c-mpl was crucial 
for the production of platelets, and likely the receptor for an 
unknown ligand required for thrombopoiesis.29 Additional 
evidence from these c-mpl knock-out mice revealed they had 
normal levels of red and white cells, but had an 85% decrease 
in platelet levels.30 Further study of these c-mpl knock-out 
mice suggested that Mpl, in addition to playing an important 
role in the later stages of megakaryocyte production and 
maturation, may also play a key role in the production and 
regulation of bone marrow stem cells.31,32
Finding and characterizing TPO
Although the search for TPO had been undertaken for decades, 
several groups working independently published their find-
ings in the cloning of the c-mpl ligand, which was eventually 
termed thrombopoietin (TPO).33–36 Initial studies showed that 
TPO increased the platelet counts of mice, promoted the pro-
liferation and differentiation of megakaryocytes, and mapped 
to chromosome 3q27.37,38 In addition to increasing platelet 
production, TPO was observed to affect the longevity and 
proliferation of hematopoietic stem cells.39 Working in 
concert with Epo, stem cell factor, and IL-11, TPO is an 
integral factor in megakaryocyte growth, development, and 
increases the nuclear ploidy of the maturing megakaryocyte.40 
After thrombopoiesis has occurred, TPO continues to play a 
role in platelet signaling. Under physiologic concentrations, 
TPO “primes” the platelet to be more sensitized to the effects 
of thrombin, leading to improved platelet aggregation and 
secretion.41,42
Cellular effects of TPO binding to Mpl
When TPO binds to Mpl, several intracellular signaling cas-
cades occur. While a complete review is beyond the scope 
of this article, and has been expertly reviewed elsewhere,43 
a brief description follows.
Upon TPO binding with Mpl, the receptor undergoes 
homo-dimerization,44 which is thought to initiate the intra-
cellular signaling cascade. Janus kinase 2 (JAK2) is rapidly 
activated via transphosphorylation, and phosphorylates Mpl 
on tyrosine-112, which is necessary for intracellular signal-
ing. The phosphorylation of serine-18, which is required 
for binding of phospho-JAK2 occurs by an undetermined 
kinase.45–47 The phosphorylation of Mpl facilitates binding 
of Src homology 2 (SH2) signaling adaptor proteins. This 
enhances the binding of the signal transducers and activators 
of transcription (STAT), specifically STAT3 and STAT5 in 
Mpl cells.48,49 These in turn are phosphorylated by JAK-2, 
causing STAT3/STAT5 to dimerize and translocate to the 
nucleus, leading to their effects upon transcription.43 Other 
proteins that have been implicated in binding via their SH2 
domains to Mpl include Shc, Vav, Grb2, SHIP, and SOS, 
among others.50,51Biologics: Targets & Therapy 2009:3 502
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In addition to the binding of SH2 proteins, phosphorylated 
Mpl  creates  a  binding  site  for  Shc,  which  is  then 
phosphorylated45,49 and recruits Grb2 and Sos. This leads to 
Ras activation,49 recruiting Raf, with subsequent activation 
of mitogen-activated protein kinase (MAPK)/extracellular-
signal receptor kinase (ERK).50 Activation of MAPK leads to 
megakaryocyte development, an increase in nuclear ploidy, 
and endomitosis.52,53
While not completely understood, TPO stimulated activa-
tion of Mpl leads to the activation of phosphatidylinositol-3 
kinase (PI3K). This enzyme catalyzes the phosphoryla-
tion of PI4P and PI4,5P to make PI-3,4P2 and PI-3,4,5P3, 
respectively. Once created in the cellular membrane, 
these phospholipids allow for the docking of proteins 
with pleckstrin homology (PH) domains. Key among these 
phosphatidylinositol-binding proteins is the Akt kinase, a pro-
tein that contributes to numerous cellular events affecting 
proliferation and survival.43 PI3K, with its adaptor protein 
p85, associates with Gab2 and IRS2. This also leads to the 
activation of ERK in a Ras-independent fashion.
TPO in disease states
In chemotherapy-induced thrombocytopenia (CIT), TPO 
levels were noted to be elevated.54 By comparing it to the 
physiologic behavior of Epo, it was inferred that in throm-
bocytopenic states, levels of TPO would be increased, just 
as is seen in certain forms of anemia. As might be expected, 
TPO levels were elevated in aplastic anemia and acute 
lymphoblastic leukemia, whereas the TPO concentration in 
essential thrombocytosis were not raised.55 However, when 
levels of TPO were examined in patients with ITP, TPO levels 
were observed to be within the normal range. This raised the 
possibility that part of the defect in ITP may be due to a lack 
of elevated TPO levels.56,57 These observations were difficult 
to reconcile with the prevailing notion that TPO functioned 
in a fashion similar to Epo, especially when megakaryocyte 
hyperplasia was noted on bone marrow biopsies. Yet, these 
observations fueled further study into the mechanisms of 
platelet production.
Using distinct patient populations with thrombocyto-
penia, TPO levels were examined in patients with aplastic 
anemia, ITP, post-transfusion purpura (PTP), drug purpura 
(DP), and X-linked thrombocytopenia (XLTP). These values 
were compared to the platelet count and megakaryocyte mass, 
whereupon it was observed that patients with ITP, PTP, DP, 
and XLTP had seemingly inappropriately low TPO levels.58 
It has also been observed that leukemic myeloid cells with 
a functional Mpl, bound TPO and lowered its circulating 
level, which returned to normal levels following induction 
chemotherapy.59 The observations in the different TPO levels 
could be explained by the relative increase in megakaryocyte 
mass that has been noted in the specific low TPO states, an 
observation that has been well-known in ITP.
This, along with numerous other observations, have 
confirmed a model for TPO production and regulation nearly 
thirty years after it was first proposed.60 The majority of TPO 
is constitutively produced by the liver, and to a lesser extent 
the kidneys and bone marrow stroma. Circulating platelets 
and bone marrow megakaryocyte mass directly regulate TPO 
levels by internalizing receptor bound TPO61 and degrad-
ing it, instead of modifying TPO production or release.62,63 
Therefore, an increase in either platelet or megakaryocyte 
mass causes a decrease in the circulating TPO level.43 This 
so-called “sponge theory”64 of TPO regulation is analogous 
to the neutrophil granulocyte-colony stimulating factor 
(G-CSF) receptor-mediated clearance of G-CSF.65
From bench to bedside:   The use 
of recombinant TPO to treat 
thrombocytopenia
Once the sequence for TPO became known, recombinant 
versions were created to use clinically. Two forms were tested 
in a variety of circumstances: recombinant human (rhTPO) 
and polyethylene glycol recombinant megakaryocyte growth 
and development factor (PEG-rHuMGDF). rhTPO is a full-
length glycosylated form of TPO.66 The PEG-rHuMGDF is 
a recombinant truncated fragment of TPO that still has the 
ability to bind and activate Mpl,67 with the linkage to PEG 
that greatly enhances its half-life.68,69 Both rhTPO and PEG-
rHuMGDF produce robust increases in platelet counts after 
a delay of 4–6 days, and have prolonged half-lives.70
Nonmyeloablative chemotherapy-induced 
thrombocytopenia
In addition to leukopenia caused by nonmyeloablative 
chemotherapy, CIT is a common complication. A clinical 
trial examined the role of recombinant TPO’s in treating 
thrombocytopenia resulting from carboplatin and paclitaxel 
in advanced lung cancer treatment. It was observed that PEG-
rHuMGDF-treated study subjects had less of a nadir platelet 
count, and recovery to base-line levels were hastened by 
therapy with little adverse effects.69 Similar benefits were also 
shown in patients who received carboplatin for treatment of 
gynecologic cancers.71 In a phase I/II study of patients undergo-
ing treatment with chemotherapy for sarcoma, patients given Biologics: Targets & Therapy 2009:3 503
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a single intravenous dose of rhTPO demonstrated increased 
platelet counts by day 4, and peak platelet counts between days 
10–15 before returning towards baseline. Although rhTPO 
was generally well tolerated, one patient transiently developed 
an antibody against TPO.72 However, there is no evidence or 
recommendations for the use of thrombopoiesis-stimulating 
agents in this setting, as exists for G-CSF.
Use in thrombocytopenia of Hiv
The use of recombinant TPO’s was investigated in throm-
bocytopenic patients with HIV. Initially, PEG-rHuMGDF 
was tested in HIV-infected chimpanzees, with encouraging 
results.73 Three doses of PEG-rHuMGDF produced a 10-fold 
increase in the platelet count, along with a 30-fold increase 
in megakaryocytes.73 These experiments led to an early 
clinical trial in six patients with HIV and thrombocytopenia. 
This study demonstrated that a 5 µg/kg/dose administered 
subcutaneously twice weekly produced a 10-fold increase 
in platelet number within two weeks of treatment. This 
increased platelet count persisted throughout the 16 weeks 
of treatment, but returned to the thrombocytopenic levels 
within two weeks of cessation of therapy.74
enhancing yields in platelet donation
PEG-rHuMGDF was also evaluated in clinical trials to deter-
mine if it could increase the amount of platelets collected 
during a donation. In a set of companion studies,75,76 healthy 
platelet donors were treated with a single injection of placebo, 
1 µg/kg, or 3 µg/kg of PEG-rHuMGDF. Platelets collected 
via apheresis were then transfused to adult patients, who 
required prophylactic platelet transfusions as a result of CIT. 
The initial phase of the study found that platelet donors treated 
with PEG-rHuMGDF, as expected, achieved higher platelet 
counts in a dose dependent fashion. Furthermore, a higher 
number of platelets were collected at greater collection 
efficiency when compared to placebo. The volunteers 
tolerated the treatment well, with only headache reported as 
a side effect.75 The latter phase of these two studies examined 
the efficacy of the platelets that were obtained from pre-
treated donors in patients with CIT.76 It was observed that 
the thrombocytopenic patients who received platelets from 
PEG-rHuMGDF treated donors, had higher post-transfusion 
counts, and were able to go longer until receiving the next 
platelet transfusion.76
A novel treatment option for iTP
PEG-rHuMGDF and rhTPO were also tested in the treatment 
of chronic refractory ITP. Three out of four patients with ITP 
who were given 0.5 µg/kg /day of PEG-rHuMGDF for up 
to seven days had an increase in their platelet counts. The 
one subject whose platelets did not rise, had a decrease in 
bleeding episodes.77 PEG-rHuMGDF was also used to treat 
a rare variant of ITP, cyclic thrombocytopenia. In the treat-
ment of a refractory patient, who had hemorrhagic symptoms 
for almost 50 years, despite numerous immunosuppressive 
medications, PEG-rHuMGDF was effective in inducing safe 
platelet levels without significant side effects.78 rhTPO was 
used successfully in the treatment of a 41-year-old woman 
with chronic refractory ITP. Notably, this patient became less 
responsive, and for shorter durations with each successive 
cycle of rhTPO therapy even though antibodies to rhTPO or 
endogenous TPO were never detected.79
Myelodysplastic syndrome and aplastic 
anemia
Preliminary studies have evaluated the use of PEG-rHuMGDF 
for the treatment of myelodysplastic syndrome (MDS) and 
aplastic anemia. In vitro laboratory data reveals that when 
bone marrow cells harvested from patients with MDS are 
incubated with TPO, granulocyte and erythroid precursors 
are stimulated. This raises the possibility that administration 
of this growth factor may stimulate the malignant clones in 
the bone marrow.80,81 Yet despite this potential drawback, 
limited human data with the use of TPO agents gives hope 
for cautious optimism. An isolated case report in a throm-
bocytopenic woman treated with PEG-rHuMGDF for over 
a year demonstrated an increase in both platelet and red cell 
counts.82 Shortly after this publication, another case report 
detailed the use of PEG-rHuMGDF in aplastic anemia. In 
this situation, daily administration of PEG-rHuMGDF led to 
a tri-lineage response, eliminating the need for transfusions 
or additional treatment.83
Use in myeloablative chemotherapy
The first human trial of PEG-rHuMGDF in the setting of 
induction and consolidation chemotherapy in acute myelog-
enous leukemia (AML) involved 108 adult AML patients. 
They were randomized to receive placebo, a single dose 
for seven days, or 21 days of PEG-rHuMGDF.84 Although 
PEG-rHuMGDF was well tolerated, and did not stimulate the 
growth of leukemic cells, it did not shorten the duration of 
the platelet transfusion-dependent period (the primary end-
point). In this trial, PEG-rHuMGDF enhanced the rebound 
thrombocytosis upon platelet count recovery. In another 
de novo trial of AML patients who were treated at the end 
of induction or consolidation chemotherapy with placebo, Biologics: Targets & Therapy 2009:3 504
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2.5 µg/kg/day, or 5 µg/kg/day of PEG-rHuMGDF, also had 
disappointing results.85 Although recovery thrombocytosis 
was highest among the 5 µg/kg/day group, there were no 
significant benefits to patients receiving PEG-rHuMGDF 
with respect to the number of platelet transfusions required or 
the duration of the platelet nadir. A similar lack of benefit was 
also seen in patients with advanced breast cancer, who were 
undergoing autologous bone marrow transplant.86 In this trial, 
patients were randomized to receive either placebo, 1.0, 2.5, 
5.0, 7.5, or 10.0 µg/kg/day, starting on the day of transplanta-
tion until platelet counts recovered, or for 21 days. Although 
well tolerated, even the highest dose of PEG-rHuMGDF 
failed to induce earlier platelet engraftment.
The demise of recombinant TPO
The initial studies of the recombinant TPO’s showed that 
they have enormous potential in raising the platelet count in 
a variety of conditions associated with thrombocytopenia. 
Unfortunately, it was noted that patients and healthy volun-
teers developed antibodies not only against the exogenously 
administered PEG-rHuMGDF, but also against endogenous 
TPO. These anti-TPO antibodies resulted in sustained 
thrombocytopenia.87 Similarly, 13 of the 325 healthy vol-
unteers, and 4 of the 650 oncology patients treated with 
PEG-rHuMGDF developed persistent thrombocytopenia 
attributable to immune responses against the drug, as well 
as against endogenous TPO. In addition to thrombocytope-
nia, pancytopenia developed in a patient who had received 
PEG-rHuMGDF with six cycles of chemotherapy.88 Almost 
all of these reactions were seen in patients treated with 
PEG-rHuMGDF. A single patient with sarcoma developed 
an antibody against full-length TPO. However, this reaction 
was considered transient and not clinically relevant.72 Notably, 
this response was never seen immediately, and was always 
mediated by the IgG4 sub-type.87 Even though IgG4 only 
accounts for approximately 5% of the total IgG concentration, 
it is notable that this immunoglobulin isotype causes other 
autoimmune responses, including antifactor VIII antibodies 
seen in congenital and acquired hemophilia.89 Typically, 
this response arises from B-cells arising from T helper cells 
Th2 stimulation.90 Nevertheless, the development of auto-
antibodies against TPO effectively halted any further clinical 
development of the recombinant TPO agents.
emergence of TPO mimetics
The observation that the recombinant TPO’s could elicit the 
development of an immune response against exogenous, 
as well as endogenous TPO provoked the development of 
alternative TPO mimetics. This led to rationally designed 
TPO receptor (TPOr) agonists, which were developed 
because they were predicted to have a very low potential for 
generating an antibody response. These novel compounds 
have no homology to endogenous TPO, yet are able to 
activate the TPOr. Progress in this area represents the most 
exciting and innovative area of ITP and thrombocytopenia 
treatment in decades, and has the potential for changing the 
landscape of therapeutics for thrombocytopenia.
Prior to the emergence of neutralizing antibodies with the 
initial trials of the recombinant TPO compounds, pioneering 
research into alternative TPOr agonists were performed 
with phage display libraries. Screening this library revealed 
a 14-amino acid peptide that bound to the TPOr, yet lacked 
homology to TPO.91 Furthermore, when the peptide was 
dimerized, it was able to bind to the TPOr with the same 
affinity as TPO, yet it was one tenth the size. The dimerized 
peptide had the same effect as rhTPO in producing an increase 
in megakaryocyte colony numbers.91 The dimerized peptide 
was modified by derivatizing the N-termini of both ends of 
the dimer, and then pegylated to increase half-life.92 While 
this compound (now known as GW395058) is not undergoing 
clinical trials in humans, it opened the door for other TPO 
mimetics that do not share homology with TPO, thereby 
decreasing the risk of eliciting an antibody response.
Drawing upon alternative ways to bind to and activate 
the TPOr, a murine monoclonal antibody (named BAH-1)93 
possessing agonist activity towards TPOr was generated. 
In vitro studies showed that BAH-1 bound to megakaryocyte 
progenitors, and stimulated their growth and maturation. The 
fully intact antibody is able to stimulate the TPOr, while 
fragment antigen-binding (Fab) fragments of BAH-1 can not, 
suggesting that BAH-1, like native TPO BAH-1 functions 
by inducing TPOr dimerization upon ligand binding. While 
BAH-1 was able to increase megakaryocyte progenitors, 
the use of BAH-1 in mice that were myelosuppressed was 
only modestly successful.93 Although this compound did not 
undergo further clinical testing, it did provide the “proof of 
principle” for further novel compounds.
TPO mimetics used in humans
Romiplostim (Nplate™, Amgen, Thousand Oaks, CA) is 
the first TPOr agonist to be approved by the US Food and 
Drug Administration (FDA). Approved for use in humans on 
August 22nd, 2008, romiplostim was originally studied as the 
Amgen megakaryopoiesis protein-531 (AMG-531). It was 
granted orphaned drug status in 2003, and fast-tracked by the 
FDA in 2004.94 Romiplostim is composed of four peptides Biologics: Targets & Therapy 2009:3 505
Novel treatments of thrombocytopenia Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
that are capable of binding to the TPOr, and are fused to an 
fragment crystallizable (Fc) carrier domain. This unique drug 
structure known as a “peptibody” is the first type of com-
pound of this drug class to be used in humans95 (Figure 1). 
Since the TPOr-binding regions of romiplostin do not share 
sequence homology with TPO, an immune response against 
romiplostin should not cross react with native TPO. The Fc 
domain of romiplostim binds to the FcRn salvage receptor, 
which then undergoes endothelial recirculation, significantly 
prolonging the life of romiplostim in plasma.96 In addition to 
increasing platelet counts, romiplostim augments the growth 
of megakaryocyte colony-forming units, and megakaryocyte 
maturation.97
Phase i/ii studies
Romiplostim underwent two phase I/II open label dose 
escalation trials in study subjects with chronic ITP.98,99 In 
this initial study, sixteen subjects with ITP were given 30, 
100, 300, or 500 µg of romiplotsim, and platelet counts were 
measured regularly. A study subject given the highest dose of 
500 µg achieved a platelet count of 1,062/µl. This patient was 
withdrawn from the study, and this dose was discontinued. 
Only one other patient had an unacceptably high platelet count 
when administered the 300 µg dose. Of the remaining fourteen 
subjects, twelve had increases in platelet counts that occurred 
within ten days of dosing, with a mean increase of 20 in 
platelet count above baseline. Adverse events were minimal, 
and were limited to headache and rebound thrombocytopenia 
when the study drug was discontinued. Analysis of the amount 
of romiplostim used led to a weight based conversion, where 
platelet responses were seen at doses 1 µg/kg.98
A follow-up phase I/II study involved nine US centers 
and 24 subjects with chronic ITP. Study participants were 
treated with a weight based schedule of 0.2, 0.5, 1, 3, 6, and 
10 µg/kg. Doses of romiplostim 1 µg/kg were found to be 
ineffective in raising the platelet count, whereas higher doses 
(3–10 µg/kg) were more effective. Responses were gener-
ally seen in about a week, with peak responses occurring 
10–14 days afterwards.99
The phase II portion was a double-blind, placebo-
controlled trial, with four subjects in a placebo group 
and 17 in the treatment arm receiving 1, 3, or 6 µg/kg of 
romiplostim.99 After three weeks, the 6 µg/kg dose was 
eliminated after a study participant developed a platelet 
count of 520. However, weekly subcutaneous administration 
of 1 and 3 µg/kg increased the platelet counts in a majority 
of patients, as twelve out of sixteen patients had increases in 
their platelet counts. The median time for response was 18 
and 19 days, for 1 and 3 µg/kg, respectively. As was observed 
in the initial studies, adverse events were mild in severity. 
Ecchymoses and headache remain common findings, and 
two study subjects had worsening thrombocytopenia after 
the cessation of romiplostim.99
Phase iii trials
Phase III trials of romiplostim enrolled patients with ITP, 
who might, or might not have had a splenectomy.100 Two 
simultaneous trials were conducted in a double-blind, placebo 
controlled, and international multicenter trial. Patients were 
enrolled 2:1 for romiplostim vs placebo. Sixty-three study 
participants were enrolled in the splenectomy group, and 62 
in the nonsplenectomy group. Patients were dosed weekly 
with romiplostim or placebo for 24 weeks, with dose adjust-
ments made to maintain a platelet count of 50,000–200,000. 
While concurrent use of oral immunosuppressant agents and 
rescue medications was allowed, study subjects were not 
enrolled if recently treated with IVIg or anti-D, alkylating 
agents, rituximab, or other modalities. The primary outcome 
was a “durable platelet response”, which was defined as a 
weekly platelet count of 50 during six or more weeks of the 
last eight weeks of treatment. A “transient platelet response” 
was defined as “four or more weekly platelet responses with-
out a durable platelet response from weeks 2 to 25.100
In addition to analyzing the effects of romiplostim on 
ITP, researchers were able to show that treatment with it was 
capable of improving the quality of life (QoL) of patients with 
ITP.101 Using the same population in the phase III study, it 
was observed that patients, who had undergone splenectomy, 
had lower baseline scores when compared to nonsplenecto-
mized patients. While this may be attributed to a more severe 
or chronic form of the disease, the splenectomized patients 
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had a greater improvement in their QoL scores, than patients 
with intact spleens, or patients on placebo. Nonsplenecto-
mized patients had a higher QoL in the activity scales when 
compared to patients on placebo.101
The results from a single-arm, long-term safety and 
efficacy study, involving 142 study subjects, some followed 
for as long as three years, has been reported, and has under-
gone peer review.102 The majority of treated subjects (87%) 
were able to mount a platelet response without developing 
resistance to the effects of romiplostim. Furthermore, when 
compared to the phase III results, subjects followed in this 
long-term observational study had a lower number of bleed-
ing episodes. Those that had hemorrhagic symptoms, did so 
only at platelet counts of 30 × 109/L. This lends additional 
support to the observation that bleeding in ITP occurs at 
lower values. An added benefit that was noted during this 
study was that 84% of the subjects treated with romiplostim 
were able to discontinue their concurrent ITP treatments. 
While increasing the platelet count, it must be noted that 
romiplostim is ineffective in altering the pathophysiology 
of ITP, since platelet counts return to baseline following its 
discontinuation.102
Adverse effects of romiplostim
Throughout the studies evaluating the safety and efficacy of 
romiplostim, to date, no antibodies directed against TPO have 
been detected, although one subject had a transient antibody 
response to romiplostim.102 As stated above, the most com-
monly reported adverse effects have been bruising and mild 
to moderate headaches.
The most significant known adverse effect of romiplostim 
is the potential for increasing deposits of reticulin in the bone 
marrow. Rodents treated with PEG-rHuMGDF were found to 
have increased marrow reticulin. In these animals, the fibrosis 
is mediated by transforming growth factor-β1 (TGF-β1).103–105 
Additional support for the role of TGF-β1 comes from 
experiments in mice that are engineered to overexpress TPO. 
When these mice are lethally irradiated and then rescued with 
wild-type hematopoietic stem cells (HSC) or HSC that are 
engineered to be TGF-β1 null (TGF-β1-/-) it was observed 
that the TGF-β1-/- were protected against the development 
of reticulin deposits as compared to their wild-type litter-
mates.106 A similar effect has been observed in human 
subjects receiving romiplostim, although the significance of 
this increase in reticulin is unknown. This was first observed 
in two study subjects during the phase I/II studies,99 and 
subsequently monitored in the phase III studies.100 Eight 
study subjects were found to have an increase in bone marrow 
reticulin in the long-term safety study.102 In all, 10 out of 
271 ITP study subjects have developed increased reticulin. 
However, it has been observed that cessation of therapy leads 
to a normalization of reticulin level.107 The participants who 
developed an increase in bone marrow reticulin were found 
to have either undergone splenectomy, required extensive 
treatment for ITP, received high doses of romiplostim, or 
had a minimal response to the treatment.
A bone marrow biopsy is not required prior to initiation 
of romiplostim. Instead, careful analysis of the peripheral 
blood smear before and during treatment is recommended. 
If the peripheral blood smear shows signs of myelofibrosis 
(such as nucleated red cells, dacrocytes) or other cytopenias 
develop, romiplostim should be stopped and a bone mar-
row biopsy, with attention to reticulin staining, is strongly 
encouraged.108
Another risk associated with romiplostim is an exacerba-
tion of thrombocytopenia after it is discontinued. Four study 
participants in the phase I/II study had a transient worsening 
of their baseline thrombocytopenia after romiplostim was 
discontinued, leading one to experience vaginal bleeding.99 
Recommendations are to monitor complete blood counts after 
stopping romiplostim and to consider alternative therapies if 
clinically indicated.108
With the increase in platelet counts, theoretical concerns 
have existed over an increased risk of thrombosis. While 
there was no noticeable effect in platelet aggregometry 
studies performed in healthy Japanese males,109 thrombotic 
and thromboembolic events have been observed in the 
clinical trials evaluating romiplostim. A total of 12 events 
were observed in seven patients, and included deep vein 
thrombosis, myocardial infarction, and transient ischemic 
attack.102 However, the study investigators felt that this rate 
of thrombotic events was no different when compared to the 
natural history of thrombosis in ITP patients.
eltrombopag
Like romiplostim, eltrombopag (Promacta™; GlaxoSmith-
Kline, Philadelphia, PA) is another TPOr agonist that has been 
FDA-approved. However, it is unique in that it is a nonpeptide 
small molecule that binds to the TPOr (Figure 2). Using a 
high-throughput cell based assay, several hundred thousand 
nonpeptide compounds were tested from chemical compound 
libraries. The study identified hydrazinonaphthalene and 
azonaphthalene compounds as potential nonpeptide activa-
tors of the TPOr.110 From this initial screen, these compounds 
were further modified for increased bioavailability, and 
improved pharmacokinetics. Eventually, the test molecule Biologics: Targets & Therapy 2009:3 507
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SB-497115111 (now termed eltrombopag), was designed, and 
had the advantage of being the first orally bioavailable non-
peptide-based TPOr agonist. Preclinical data on the biologic 
characteristics of eltrombopag shows that it is able to bind 
to the TPOr in a noncompetitive fashion with endogenous 
TPO. Using thymidine incorporation assays, eltrombopag is 
additive to the effects of TPO, ultimately reaching a plateau 
in their combined effects. Furthermore, using cell based 
assays, eltrombopag binds almost exclusively to the TPOr, 
without binding to the Epo, G-CSF, IFN-α, IFN-γ, or IL3 
receptors.112,113 When eltrombopag binds to the TPOr, the 
JAK/STAT5 pathway is activated, leading to MAPK stimu-
lation.110,113 These intracellular events help to explain how 
eltrombopag leads to the proliferation and differentiation of 
megakaryocytes, ultimately causing the observed increase 
in platelet counts. The effects of eltrombopag appear to be 
limited to platelet production, as in vitro assays show that 
it does not induce or inhibit platelet aggregation, whereas, 
rhTPO can enhance ADP-mediated platelet aggregation.114
Phase i studies
Clinical trials with eltrombopag were initiated in a phase 
I study with 73 participants who were given placebo and 
eltrombopag at doses from 5–75 mg daily.115 It was observed 
that doses greater than 30 mg administered for ten days 
produced measurable increases in platelet counts fourteen 
to 16 days later, with higher response rates observed at the 
50 and 75 mg doses. As could be expected, withdrawal of 
eltrombopag caused the platelet counts to return to baseline 
levels. In this phase I study, there was no difference in the 
incidence of adverse events between the eltrombopag or 
placebo groups, and platelet aggregation profiles remained 
unchanged.115
Pharmacokinetic studies performed during the phase I 
studies indicated that calcium salts, particularly in the form 
of antacids, decreased the gastrointestinal absorption of 
eltrombopag. This observation ultimately led to the recom-
mendation that a four-hour separation occur between the 
ingestion of the medication and other compounds known to 
contain metal cations, particularly calcium.116
Phase ii studies
Eltrombopag was next evaluated in two distinct patient 
populations with thrombocytopenia: 1) patients with 
ITP117 or 2) thrombocytopenic patients with cirrhosis 
from hepatitis C, who were to be treated with ribavirin 
and pegylated INF.118 A phase II study with 117 ITP 
subjects was performed where subjects were treated for 
six weeks with placebo, 30, 50, or 75 mg daily, and were 
stratified according to use of concurrent ITP medica-
tions, splenectomy, and platelet counts of greater than 
15,000/µl. The primary endpoint was set to be a platelet 
count 50,000/µl, and the secondary endpoints focused 
on safety, QoL, and incidence of bleeding symptoms. 
A greater percentage of study participants responded to the 
higher doses, with 81%, 70%, 28%, and 11% reaching the 
primary endpoint when treated with 75 mg, 50 mg, 30 mg 
of eltrombopag, or placebo, respectively. No differences 
were noted between the responses in patients who did, or 
did not have a splenectomy, or based on either age or race. 
Investigators noted that study subjects treated at the 75 and 
50 mg doses had decreased bleeding episodes, implying 
adequate hemostatic capability of the increased platelet 
count. Adverse effects were similar in all study groups, 
including the placebo arm, with the most common reported 
symptom being headache.117
A second phase II study was performed in patients with 
thrombocytopenia from liver disease and concurrent hepatitis 
C infection to assess if eltrombopag could increase the plate-
let count to allow antiviral therapy with ribavirin and INF.118 
Again, placebo, 30 mg, 50 mg, or 75 mg daily for four weeks 
was used in adult patients with baseline platelet counts of 
20,000–70,000/µl, and were stratified according to baseline 
platelet counts of 20,000–50,000/µl or 50,000–70,000/µl. 
In this international, multi-center, double-blind, random-
ized, placebo-controlled trial, subjects were monitored for 
responses to eltrombopag, and if successful, they underwent 
treatment with ribavirin and IFN, while continuing their 
allocated treatment. The majority of subjects responded 
to eltrombopag (71%–91%), and 36%–65% were able to 
complete 12 weeks of hepatitis C therapy. Even when platelet 
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counts fell, presumably due to the antiviral treatment, the 
platelet counts still remained above baseline, allowing for 
the continuation of treatment.118 As with the ITP treatment 
study,117 headache was the most commonly reported side 
effect.
Phase iii studies
One hundred and fourteen patients with ITP were enrolled 
into a double-blind, placebo-controlled study, using 50 mg or 
75 mg of eltrombopag daily.119 They were stratified according 
to splenectomy status, need for concurrent ITP therapy, and a 
platelet count 15,000/µl. The primary endpoint of the study 
was to achieve a platelet count 50,000/µl in six weeks, with 
secondary endpoints of platelet counts, proportion of patients 
with platelet counts 50,000/µl, bleeding symptoms, and 
safety, among others.
Patients who received eltrombopag had significantly 
greater odds of achieving a platelet response 50,000/µl 
than did the placebo group. No impact of concurrent ITP 
treatment or effect of splenectomy was noted. Bleeding 
symptoms were lower in the treatment than in the placebo 
arm, implying that the increased platelets were sufficient in 
number and quality for hemostasis.
Side effects of eltrombopag
As with romiplostim, the side effects of eltrombopag appear 
to be mild to moderate, and are limited to such symptoms such 
as headache, dry mouth, nausea, myalgia, and/or arthralgia.117–
119 To date, no immune response against eltrombopag or to 
TPO has been observed in study participants.
An effect upon liver function, as evidence by a transami-
nitis, led to a “black-box” warning following FDA approval. 
Observed in three study subjects in the phase II trial,117 and 
then reported in a total of six patients in the phase III trial,119 
the degree transaminitis was at least twice the upper limit of 
normal, causing the withdrawal of one study participant. As 
a result, it is recommended that alanine aminotransferase, 
aspartate aminotransferase, and bilirubin levels be checked 
at baseline, bi-monthly as dose adjustments are made, and 
then monthly once the patient is on a stable dose.120 Increased 
levels should be re-checked in 3–5 days and monitored for 
resolution, stabilization, or increase. If levels increase 3 × 
the upper limit of normal, are progressive, persist longer than 
4 weeks, are accompanied by an increase in direct bilirubin, 
or associated with other clinical symptoms of hepatic injury, 
then eltrombopag should be discontinued.120
Use of eltrombopag may also be associated with the 
development or progression of cataracts. One study subject in 
the placebo arm and two in the treatment arm of the phase III 
study had progression of their existing cataracts. The study 
investigators revealed that these three patients had also been 
treated with corticosteroids.119 It is recommended that an oph-
thalmologic exam should be performed during initiation of 
therapy and that treated patients be monitored regularly.120
After eltrombopag is discontinued, the platelet count is 
expected to return to baseline. As was noted with romiplos-
tim, a “rebound thrombocytopenia” may occur, predisposing 
the patient towards hemorrhagic symptoms. Two study 
subjects in the phase III study suffered bleeding episodes 
when their platelet count fell to 10,000/µl, which was lower 
than their baseline level.119
Another risk associated with the use of eltrombopag 
is thrombosis. Physicians are cautioned against using 
doses that excessively raise the platelet count. A total of 
11 thromboembolic events were noted in the clinical trials 
of eltrombopag,121 leading the FDA to caution the use of this 
mediation in patients with known risk factors for venous 
thromboembolism.120
As was observed with romiplostim, an increase in the 
formation of bone marrow reticulin was noted. In all, seven 
of the 19 study subjects in the extension study were noted to 
have bone marrow reticulin formation, although two of these 
subjects had reticulin deposition at baseline.121 Physicians 
are encouraged to evaluate the peripheral blood smear, with 
attention to erythrocyte morphology. After a stable dose has 
been achieved, regular examination of the peripheral smear 
and complete blood count is recommended. Any cytopenia or 
suggestion of morphologic abnormality, eltrombopag should 
be discontinued and a bone marrow biopsy with reticulin 
staining is recommended.120
Other compounds
While romiplostim and eltrombopag are the only FDA-
approved TPO mimetics, there are a number of other 
compounds that have been investigated in humans. While 
limited to reports in abstract form, they represent possible 
“back-ups” to those that are currently available. These potential 
agents include SB-559448, an oral nonpeptide TPOr agonist 
that has undergone phase I study in humans;122 AKR-501 
which has also undergone a phase I study and is found to be 
effective in raising platelet counts in healthy volunteers.123
TPO mimetics in development
Minibodies
Alternative mechanisms of TPOr activation include the 
creation of a “minibody,” which is derived from an anti-Mpl Biologics: Targets & Therapy 2009:3 509
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antibody.124 Upon binding to the Mpl receptor, the minibody 
causes dimerization of the receptor, leading to its activation. 
Two such novel molecules have been described, VB22B 
sc(Fv)2 and TA136 sc(Fv)2. Both agents were effective in 
increasing platelet counts in vitro, and TA136 sc(Fv)2 shows 
promise in being the first thrombopoietic agent that may be 
effective in activating the dysfunctional receptor in congenital 
amegakaryocytic thrombocytopenia.124
Fab 59
As mentioned above, screening of peptide libraries led to the 
discovery of amino acid sequences that could bind to, and 
activate TPOr.91 One such peptide, AF12505, was inserted 
into the heavy chain (HC) complementarity determining 
region (CDR) of the human tetanus-toxoid antibody.125 This 
configuration yielded a molecule that was just as effective 
as rhTPO in stimulating the TPOr, and had a much longer 
in vivo half-life than the dimerized peptide, AF13948. 
Researchers have posited that this design might have 
advantages over a peptibody design because the Fc region 
is eliminated, thereby theoretically eliminating inadvertent 
immune stimulation.125
NiP-004
NIP-004 is another hydrazine compound identified after 
screening more than 50,000 compounds in cell proliferation 
assays.126 Analogous to eltrombopag, NIP-004 is species 
selective, and therefore will only activate the human TPOr. 
Structure-function studies identified that NIP-004-binding 
was dependent upon a histidine at position 499 of human Mpl, 
and this residue confers the species specificity.126 Preclinical 
studies suggest that this compound will stimulate megakaryo-
cyte growth similar to other TPOr agonists.
Conclusion
After many decades of basic science and clinical research, 
significant strides have been made in understanding the 
pathophysiology and treatment of thrombocytopenia. This 
deeper understanding of the mechanisms causing immune 
mediated thrombocytopenia has opened new avenues to help 
ameliorate and treat the symptoms of thrombocytopenia.
The use of nonspecific immune modulators and 
immunosuppressive agents to treat thrombocytopenia has 
given rise to targeted agents, particularly those that activate 
the TOPr. While initial trials showed great promise for the use 
of PEG-rHuMGDF and rhTPO in a variety of disease states 
and clinical applications, the development of auto-antibodies 
against the recombinant TPO molecules halted further 
development. This provided the impetus for the generation 
of novel compounds to treat thrombocytopenia.
These novel agents include peptide-based TPOr agonists 
such as romiplostim and nonpeptide compounds such as 
eltrombopag, which activate the TPO receptor. The potential 
use of all these agents represents some of the most signifi-
cant breakthroughs in the treatment of thrombocytopenia in 
decades. Who should receive these new drugs, and how they 
should be given are areas of current investigation.
However, enthusiasm for these new medications need 
to be tempered with uncertainty; not for their efficacy in 
increasing the platelet count, but for concern of their safety. 
Eltrombopag and romiplostim have not been followed pro-
spectively for a significant length of time, particularly in the 
nonstudy patient. The true incidence and impact of bone mar-
row fibrosis with the use of TPO mimetics remains unknown 
and potentially serious. Likewise, thrombotic complications 
may increase if use of TPO mimetics is broadened to the 
general population. Long-term data remains to be collected, 
detailing the clinical outcomes of patients with chronic use 
of TPO mimetics.
The use of TPO mimetics will hopefully mean a safer and 
more effective alternative for the treatment of ITP. However, 
clinical questions remain for the practitioner as to the proper 
use of the TPO mimetics in an acute case of ITP or in one who 
has failed the first round of steroid use. Could TPO mimetics 
be used instead of steroids in a patient with diabetes? What 
is the role of splenectomy now in ITP? How does use the 
of TPO mimetics change the course of ITP? In addition, it 
is very likely that the cost of TPO mimetics over extended 
periods of time will raise additional concerns, particularly 
if less expensive alternatives exist. Despite these inevitable 
issues, physicians who treat thrombocytopenia, and their 
patients, remain cautiously optimistic about the use of TPO 
mimetics in the patient with chronic refractory ITP.
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